OUR SCIENCE
Building therapeutics beyond biology
Today, the lion’s share of therapeutic innovation focuses on treatments that are heavily dependent on individual patient biology. As a result, many new treatments benefit only small groups of patients who share similar characteristics.
What if we could introduce disruptive innovation in medicine that was designed for the many, rather than the few?
By leveraging the universal laws of physics, we develop nanotherapeutics with the potential to transcend the limitations of biology-specific treatments. This approach not only broadens the therapeutic impact, but also enables our innovations to be swiftly adapted and scaled to benefit a diverse range of patients across multiple disease types.
Key advantages of our physics-based approach to nanotherapeutics
01
Nanoparticles designed to evoke specific therapeutic effects that are predictable and repeatable
02
Anti-disease activity within the body does not depend on individual patient biology
03
Scalable to treat a wide range of patients and disease types
Our therapeutic candidates
NBTXR3
Nanoradioenhancer designed to help millions of patients who are diagnosed with cancer around the world each year
NBTXR3 is the first product from our Nanoradioenhancer Platform with therapeutic potential across any solid tumor that can be treated with radiotherapy.
Curadigm Nanoprimer Platform
Redefining the way drugs are designed and developed
Our Curadigm Nanoprimer Platform leverages industry-first nanotechnology to disrupt the design and development of drugs that circulate in the blood, including next-generation precision medicines (e.g. gene therapies, RNA/DNA based therapies, oncolytic viruses, etc.), by solving the problem of therapeutic clearance by the liver.